Kura Oncology Inc (KURA) - Total Assets
Based on the latest financial reports, Kura Oncology Inc (KURA) holds total assets worth $587.79 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kura Oncology Inc - Total Assets Trend (2008–2025)
This chart illustrates how Kura Oncology Inc's total assets have evolved over time, based on quarterly financial data. Also see KURA company net worth for the company's overall valuation and market capitalisation.
Kura Oncology Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Kura Oncology Inc's total assets of $587.79 Million consist of 96.0% current assets and 4.0% non-current assets. Review KURA total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.2% |
| Accounts Receivable | $12.60 Million | 1.7% |
| Inventory | $413.00K | 0.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Kura Oncology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See KURA share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kura Oncology Inc's current assets represent 96.0% of total assets in 2025, a decrease from 100.0% in 2008.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2025, down from 100.0% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
Kura Oncology Inc Competitors by Total Assets
Key competitors of Kura Oncology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Kura Oncology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.73 | 6.16 | 25.03 |
| Quick Ratio | 4.71 | 6.16 | 25.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $441.25 Million | $552.90 Million | $526.98 Million |
Kura Oncology Inc - Advanced Valuation Insights
This section examines the relationship between Kura Oncology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.00 |
| Latest Market Cap to Assets Ratio | 1.36 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | $738.36 Million |
| Market Capitalization | $1.01 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Kura Oncology Inc's assets above their book value (1.36x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Kura Oncology Inc's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Kura Oncology Inc (2008–2025)
The table below shows the annual total assets of Kura Oncology Inc from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $738.36 Million | -2.87% |
| 2024-12-31 | $760.16 Million | +69.32% |
| 2023-12-31 | $448.94 Million | -1.62% |
| 2022-12-31 | $456.31 Million | -14.56% |
| 2021-12-31 | $534.05 Million | -17.48% |
| 2020-12-31 | $647.21 Million | +167.47% |
| 2019-12-31 | $241.97 Million | +32.68% |
| 2018-12-31 | $182.38 Million | +90.27% |
| 2017-12-31 | $95.85 Million | +37.28% |
| 2016-12-31 | $69.82 Million | -19.98% |
| 2015-12-31 | $87.26 Million | +6232.29% |
| 2014-12-31 | $1.38 Million | +15096.29% |
| 2013-12-31 | $9.07K | +9.23% |
| 2012-12-31 | $8.30K | +23.54% |
| 2011-12-31 | $6.72K | -77.14% |
| 2010-12-31 | $29.40K | +125.84% |
| 2009-12-31 | $13.02K | +73.38% |
| 2008-12-31 | $7.51K | -- |
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapi… Read more